Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection

PLoS Pathogens

Volumn 10, Issue 1, 2014, Pages

  Maroof, Asher ^a,b   Yorgensen, Yvonne M ^a   Li, Yufeng ^a   Evans, Jay T ^a  

^a GLAXOSMITHKLINE   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL; BAGG ALBINO MOUSE; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H3N2; INTRANASAL DRUG ADMINISTRATION; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; TH17 CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TH17 CELLS;

EID: 84893718907     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003875     Document Type: Article

References (34)

1. Cox RJ, Brokstad KA, Ogra P, (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15.
2. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD, (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61: 94-99.
3. Pavot V, Rochereau N, Genin C, Verrier B, Paul S, (2012) New insights in mucosal vaccine development. Vaccine 30: 142-154.
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA, (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44.
5. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT, (2000) Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18: 2416-2425.
6. Cluff CW, Baldridge JR, Stover AG, Evans JT, Johnson DA, et al. (2005) Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73: 3044-3052.
7. Stover AG, da Silva CJ, Evans JT, Cluff CW, Elliott MW, et al. (2004) Structure-activity relationship of synthetic toll-like receptor 4 agonists. J Biol Chem 279: 4440-4449.
8. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, et al. (2012) Selective TRIF-Dependent Signaling by a Synthetic Toll-Like Receptor 4 Agonist. Sci Signal 5: ra13.
9. Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, et al. (2002) Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J Endotoxin Res 8: 453-458.
10. Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, et al. (2008) The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett 18: 5350-5354.
11. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, et al. (1992) Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 89: 358-362.
12. Heurtault B, Frisch B, Pons F, (2010) Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv 7: 829-844.
13. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, et al. (2009) Critical role of IL-17RA in immunopathology of influenza infection. J Immunol 183: 5301-5310.
14. Eichelberger M, Allan W, Carding SR, Bottomly K, Doherty PC, (1991) Activation status of the CD4-8- gamma delta-T cells recovered from mice with influenza pneumonia. J Immunol 147: 2069-2074.
15. Bettelli E, Oukka M, Kuchroo VK, (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8: 345-350.
16. Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, et al. (2012) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 19: 209-218.
17. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA, (2009) Intranasal immunization promotes th17 immune responses. J Immunol 183: 6933-6938.
18. Hamada H, Garcia-Hernandez ML, Reome JB, Misra SK, Strutt TM, et al. (2009) Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182: 3469-3481.
19. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, et al. (2009) IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182: 7353-7363.
20. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, et al. (2011) Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 186: 1666-1674.
21. Rutz S, Eidenschenk C, Ouyang W, (2013) IL-22, not simply a Th17 cytokine. Immunol Rev 252: 116-132.
22. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, et al. (2010) Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 207: 1293-1305.
23. Khader SA, Guglani L, Rangel-Moreno J, Gopal R, Junecko BA, et al. (2011) IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 187: 5402-5407.
24. Williman J, Lockhart E, Slobbe L, Buchan G, Baird M, (2006) The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine 24: 4471-4474.
25. Williman J, Young S, Buchan G, Slobbe L, Wilson M, et al. (2008) DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine 26: 5153-5158.
26. Bhan U, Ballinger MN, Zeng X, Newstead MJ, Cornicelli MD, et al. (2010) Cooperative interactions between TLR4 and TLR9 regulate interleukin 23 and 17 production in a murine model of gram negative bacterial pneumonia. PLoS One 5: e9896.
27. Wang X, Chan CC, Yang M, Deng J, Poon VK, et al. (2011) A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cell Mol Immunol 8: 462-468.
28. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
29. Fossiez F, Banchereau J, Murray R, Van KC, Garrone P, et al. (1998) Interleukin-17. Int Rev Immunol 16: 541-551.
30. Bulek K, Liu C, Swaidani S, Wang L, Page RC, et al. (2011) The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 12: 844-852.
31. Fujisawa H, (2008) Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. J Virol 82: 2772-2783.
32. Tate MD, Brooks AG, Reading PC, Mintern JD, (2011) Neutrophils sustain effective CD8(+) T-cell responses in the respiratory tract following influenza infection. Immunol Cell Biol 90: 197-205.
33. Roman E, Miller E, Harmsen A, Wiley J, Von Andrian UH, et al. (2002) CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 196: 957-968.
34. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. (2012) Preexisting influenza-specific CD4(+) T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280.